<p>诺和诺德公司（NYSE:NVO - 获取免费报告）获得了十位分析师的共识推荐评级为 “持有”，Marketbeat Ratings 报告称。一位股票研究分析师给予该股票 “卖出” 评级，四位分析师给予 “持有” 评级，五位分析师给予 “买入” 评级。在过去一年中，覆盖该股票的经纪人给出的平均十二个月目标价为 135.00 美元。</p>
<p>获取 <strong>诺和诺德公司</strong> 的提醒：</p>
<ul>
<li>维京治疗公司股票上涨但难以保持涨幅</li>
</ul>
<p>最近，一些分析师对该股票发表了看法。BMO 资本市场在周四的报告中重新发布了 “市场表现” 评级，并将诺和诺德公司的目标价下调至 64.00 美元（之前为 105.00 美元）。法国巴黎银行在周二的研究报告中开始覆盖诺和诺德公司。他们对该公司的评级为 “表现不佳”。桑福德·C·伯恩斯坦在 1 月 6 日的报告中将诺和诺德公司的评级从 “表现不佳” 上调至 “市场表现”。凯普勒资本市场在 3 月 13 日的报告中将诺和诺德公司的评级从 “持有” 上调至 “买入”。最后，斯蒂费尔·尼古拉斯在 3 月 3 日的研究报告中将诺和诺德公司的股票评级从 “买入” 下调至 “持有”。</p>
<p><strong>阅读我们最新的 NVO 股票分析</strong></p>
<h2>机构投资者对诺和诺德公司的看法</h2>
<ul>
<li>目前哪个医疗保健股票是最佳买入？</li>
</ul>
<p>几家对冲基金最近买入和卖出了该公司的股票。M. Kulyk &amp; Associates LLC 在第四季度将其在诺和诺德公司的持股增加了 3.9%。M. Kulyk &amp; Associates LLC 目前拥有该公司 3182 股股票，价值 274,000 美元，此前在上个季度又收购了 119 股。金融规划中心在第四季度将其在诺和诺德公司的持股增加了 72.4%。金融规划中心目前拥有该公司 293 股股票，价值 25,000 美元，此前在此期间又购买了 123 股。Tradewinds Capital Management LLC 在第四季度将其在诺和诺德公司的持股增加了 2.6%。Tradewinds Capital Management LLC 目前拥有该公司 4984 股股票，价值 429,000 美元，此前在此期间又购买了 124 股。Exencial Wealth Advisors LLC 在第四季度将其在诺和诺德公司的持股增加了 0.5%。Exencial Wealth Advisors LLC 目前拥有该公司 23094 股股票，价值 1,987,000 美元，此前在此期间又购买了 124 股。最后，Indie Asset Partners LLC 在第四季度将其在诺和诺德公司的持股增加了 4.2%。Indie Asset Partners LLC 目前拥有该公司 3128 股股票，价值 269,000 美元，此前在此期间又购买了 126 股。目前，11.54% 的股票由机构投资者和对冲基金持有。</p>
<h2>诺和诺德公司股票下跌 7.8%</h2>
<p>周五，NYSE NVO 的开盘价为 57.99 美元。该股票的 50 日简单移动平均线为 76.03 美元，200 日简单移动平均线为 92.13 美元。该公司的债务与股本比率为 0.62，流动比率为 0.74，速动比率为 0.55。诺和诺德公司的股价在一年内最低为 57.28 美元，最高为 148.15 美元。该公司的市值为 2602.3 亿美元，市盈率为 17.63，市盈增长比率为 0.90，贝塔值为 0.61。</p>
<ul>
<li>艾伯维股票通过进入减肥市场提升投资组合</li>
</ul>
<p>诺和诺德公司（NYSE:NVO - 获取免费报告）最后一次公布财报是在 2 月 5 日，周三。该公司报告每股收益为 0.91 美元，超出分析师的共识预期 0.88 美元，超出 0.03 美元。诺和诺德公司的股本回报率为 84.68%，净利润率为 34.81%。作为一个整体，卖方分析师预测诺和诺德公司在当前财政年度的每股收益将达到 3.84 美元。</p>
<h2>诺和诺德公司增加股息</h2>
<p>该公司最近还披露了半年度股息，已于 4 月 8 日（星期二）支付。3 月 31 日的登记投资者获得每股 0.7874 美元的股息。除息日期为 3 月 31 日（星期一）。这代表了 1.2% 的收益率。这比诺和诺德公司之前的半年度股息 0.51 美元有所增加。诺和诺德公司的派息比率目前为 49.54%。</p>
<h2>诺和诺德公司简介</h2>
<p>（获取免费报告）</p>
<p>诺和诺德公司及其子公司从事药品的研究与开发、生产和分销，覆盖欧洲、中东、非洲、中国大陆、香港、台湾、北美及国际市场。它分为两个部门：糖尿病与肥胖护理和罕见疾病。</p>
<h2>精选故事</h2>
<ul>
<li>五只我们更看好的股票超过诺和诺德公司</li>
<li>零售投资者如何交易多伦多证券交易所（TSX）？</li>
<li>关税豁免为台湾半导体的反弹铺平了道路</li>
<li>最具波动性的股票，投资者需要知道的事项</li>
<li>缓解关税：三只股票将从美元走弱中受益</li>
<li>如何投资小型股</li>
<li>博通与苹果的关系：人工智能机会与关税风险</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPU5WTw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPU5WTw"/></p>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前经过 MarketBeat 编辑团队的审核。如对该故事有任何问题或意见，请发送电子邮件至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在诺和诺德公司吗？</h2>
<p>在考虑诺和诺德公司之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，以便在更广泛的市场注意到之前进行购买……而诺和诺德公司并不在名单上。</p>
<p>虽然诺和诺德公司目前在分析师中被评为持有评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>查看这五只股票</p>

诺和诺德公司

<p>诺和诺德公司 (NYSE:NVO) 收到了十位分析师的 “持有” 共识推荐。平均十二个月目标价格为 135.00 美元。评级包括一项卖出、四项持有和五项买入。最近的分析师行动包括 BMO 资本市场将其目标价格下调至 64.00 美元，而 Kepler 资本市场则上调至买入评级。该股票目前下跌 7.8%，交易价格为 57.99 美元，市值为 2602.3 亿美元。该公司最近将其半年度股息提高至每股 0.7874 美元，收益率为 1.2%</p>

<p>Novo Nordisk A/S (NYSE:NVO - Get Free Report) has received a consensus recommendation of &#34;Hold&#34; from the ten analysts that are covering the company, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating and five have issued a buy rating on the company. The average twelve-month target price among brokers that have covered the stock in the last year is $135.00.</p>
<div class="lb-trans"><p>诺和诺德公司（NYSE:NVO - 获取免费报告）获得了十位分析师的共识推荐评级为 “持有”，Marketbeat Ratings 报告称。一位股票研究分析师给予该股票 “卖出” 评级，四位分析师给予 “持有” 评级，五位分析师给予 “买入” 评级。在过去一年中，覆盖该股票的经纪人给出的平均十二个月目标价为 135.00 美元。</p>
</div><p>Get <strong>Novo Nordisk A/S</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>诺和诺德公司</strong> 的提醒：</p>
</div><ul>
<li>Viking Therapeutics Stock Pops But Struggles to Hold Gains</li>
</ul>
<div class="lb-trans"><ul>
<li>维京治疗公司股票上涨但难以保持涨幅</li>
</ul>
</div><p>A number of analysts recently weighed in on the stock. BMO Capital Markets reissued a &#34;market perform&#34; rating and issued a $64.00 price target (down previously from $105.00) on shares of Novo Nordisk A/S in a report on Thursday. BNP Paribas initiated coverage on Novo Nordisk A/S in a research report on Tuesday. They set an &#34;underperform&#34; rating for the company. Sanford C. Bernstein upgraded Novo Nordisk A/S from an &#34;underperform&#34; rating to a &#34;market perform&#34; rating in a report on Monday, January 6th. Kepler Capital Markets raised Novo Nordisk A/S from a &#34;hold&#34; rating to a &#34;buy&#34; rating in a report on Thursday, March 13th. Finally, Stifel Nicolaus lowered shares of Novo Nordisk A/S from a &#34;buy&#34; rating to a &#34;hold&#34; rating in a research note on Monday, March 3rd.</p>
<div class="lb-trans"><p>最近，一些分析师对该股票发表了看法。BMO 资本市场在周四的报告中重新发布了 “市场表现” 评级，并将诺和诺德公司的目标价下调至 64.00 美元（之前为 105.00 美元）。法国巴黎银行在周二的研究报告中开始覆盖诺和诺德公司。他们对该公司的评级为 “表现不佳”。桑福德·C·伯恩斯坦在 1 月 6 日的报告中将诺和诺德公司的评级从 “表现不佳” 上调至 “市场表现”。凯普勒资本市场在 3 月 13 日的报告中将诺和诺德公司的评级从 “持有” 上调至 “买入”。最后，斯蒂费尔·尼古拉斯在 3 月 3 日的研究报告中将诺和诺德公司的股票评级从 “买入” 下调至 “持有”。</p>
</div><p><strong>Read Our Latest Stock Analysis on NVO</strong></p>
<div class="lb-trans"><p><strong>阅读我们最新的 NVO 股票分析</strong></p>
</div><h2>Institutional Investors Weigh In On Novo Nordisk A/S</h2>
<div class="lb-trans"><h2>机构投资者对诺和诺德公司的看法</h2>
</div><ul>
<li>Which Healthcare Stock Is the Best Buy Right Now?</li>
</ul>
<div class="lb-trans"><ul>
<li>目前哪个医疗保健股票是最佳买入？</li>
</ul>
</div><p>Several hedge funds have recently bought and sold shares of the company. M. Kulyk &amp; Associates LLC lifted its holdings in Novo Nordisk A/S by 3.9% during the fourth quarter. M. Kulyk &amp; Associates LLC now owns 3,182 shares of the company's stock worth $274,000 after acquiring an additional 119 shares in the last quarter. Center for Financial Planning Inc. raised its position in shares of Novo Nordisk A/S by 72.4% during the fourth quarter. Center for Financial Planning Inc. now owns 293 shares of the company's stock worth $25,000 after purchasing an additional 123 shares during the period. Tradewinds Capital Management LLC grew its position in shares of Novo Nordisk A/S by 2.6% in the 4th quarter. Tradewinds Capital Management LLC now owns 4,984 shares of the company's stock valued at $429,000 after purchasing an additional 124 shares during the period. Exencial Wealth Advisors LLC grew its position in shares of Novo Nordisk A/S by 0.5% in the 4th quarter. Exencial Wealth Advisors LLC now owns 23,094 shares of the company's stock valued at $1,987,000 after purchasing an additional 124 shares during the period. Finally, Indie Asset Partners LLC raised its holdings in Novo Nordisk A/S by 4.2% during the 4th quarter. Indie Asset Partners LLC now owns 3,128 shares of the company's stock worth $269,000 after buying an additional 126 shares during the period. 11.54% of the stock is currently owned by institutional investors and hedge funds.</p>
<div class="lb-trans"><p>几家对冲基金最近买入和卖出了该公司的股票。M. Kulyk &amp; Associates LLC 在第四季度将其在诺和诺德公司的持股增加了 3.9%。M. Kulyk &amp; Associates LLC 目前拥有该公司 3182 股股票，价值 274,000 美元，此前在上个季度又收购了 119 股。金融规划中心在第四季度将其在诺和诺德公司的持股增加了 72.4%。金融规划中心目前拥有该公司 293 股股票，价值 25,000 美元，此前在此期间又购买了 123 股。Tradewinds Capital Management LLC 在第四季度将其在诺和诺德公司的持股增加了 2.6%。Tradewinds Capital Management LLC 目前拥有该公司 4984 股股票，价值 429,000 美元，此前在此期间又购买了 124 股。Exencial Wealth Advisors LLC 在第四季度将其在诺和诺德公司的持股增加了 0.5%。Exencial Wealth Advisors LLC 目前拥有该公司 23094 股股票，价值 1,987,000 美元，此前在此期间又购买了 124 股。最后，Indie Asset Partners LLC 在第四季度将其在诺和诺德公司的持股增加了 4.2%。Indie Asset Partners LLC 目前拥有该公司 3128 股股票，价值 269,000 美元，此前在此期间又购买了 126 股。目前，11.54% 的股票由机构投资者和对冲基金持有。</p>
</div><h2>Novo Nordisk A/S Stock Down 7.8 %</h2>
<div class="lb-trans"><h2>诺和诺德公司股票下跌 7.8%</h2>
</div><p>NYSE NVO opened at $57.99 on Friday. The stock's 50 day simple moving average is $76.03 and its 200 day simple moving average is $92.13. The company has a debt-to-equity ratio of 0.62, a current ratio of 0.74 and a quick ratio of 0.55. Novo Nordisk A/S has a one year low of $57.28 and a one year high of $148.15. The firm has a market cap of $260.23 billion, a PE ratio of 17.63, a price-to-earnings-growth ratio of 0.90 and a beta of 0.61.</p>
<div class="lb-trans"><p>周五，NYSE NVO 的开盘价为 57.99 美元。该股票的 50 日简单移动平均线为 76.03 美元，200 日简单移动平均线为 92.13 美元。该公司的债务与股本比率为 0.62，流动比率为 0.74，速动比率为 0.55。诺和诺德公司的股价在一年内最低为 57.28 美元，最高为 148.15 美元。该公司的市值为 2602.3 亿美元，市盈率为 17.63，市盈增长比率为 0.90，贝塔值为 0.61。</p>
</div><ul>
<li>AbbVie Stock Boosts Portfolios With Entry Into Weight Loss Market</li>
</ul>
<div class="lb-trans"><ul>
<li>艾伯维股票通过进入减肥市场提升投资组合</li>
</ul>
</div><p>Novo Nordisk A/S (NYSE:NVO - Get Free Report) last announced its earnings results on Wednesday, February 5th. The company reported $0.91 earnings per share for the quarter, beating analysts' consensus estimates of $0.88 by $0.03. Novo Nordisk A/S had a return on equity of 84.68% and a net margin of 34.81%. As a group, sell-side analysts forecast that Novo Nordisk A/S will post 3.84 earnings per share for the current fiscal year.</p>
<div class="lb-trans"><p>诺和诺德公司（NYSE:NVO - 获取免费报告）最后一次公布财报是在 2 月 5 日，周三。该公司报告每股收益为 0.91 美元，超出分析师的共识预期 0.88 美元，超出 0.03 美元。诺和诺德公司的股本回报率为 84.68%，净利润率为 34.81%。作为一个整体，卖方分析师预测诺和诺德公司在当前财政年度的每股收益将达到 3.84 美元。</p>
</div><h2>Novo Nordisk A/S Increases Dividend</h2>
<div class="lb-trans"><h2>诺和诺德公司增加股息</h2>
</div><p>The company also recently disclosed a semi-annual dividend, which was paid on Tuesday, April 8th. Investors of record on Monday, March 31st were issued a dividend of $0.7874 per share. The ex-dividend date was Monday, March 31st. This represents a yield of 1.2%. This is a boost from Novo Nordisk A/S's previous semi-annual dividend of $0.51. Novo Nordisk A/S's payout ratio is currently 49.54%.</p>
<div class="lb-trans"><p>该公司最近还披露了半年度股息，已于 4 月 8 日（星期二）支付。3 月 31 日的登记投资者获得每股 0.7874 美元的股息。除息日期为 3 月 31 日（星期一）。这代表了 1.2% 的收益率。这比诺和诺德公司之前的半年度股息 0.51 美元有所增加。诺和诺德公司的派息比率目前为 49.54%。</p>
</div><h2>Novo Nordisk A/S Company Profile</h2>
<div class="lb-trans"><h2>诺和诺德公司简介</h2>
</div><p>(Get Free Report</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.</p>
<div class="lb-trans"><p>诺和诺德公司及其子公司从事药品的研究与开发、生产和分销，覆盖欧洲、中东、非洲、中国大陆、香港、台湾、北美及国际市场。它分为两个部门：糖尿病与肥胖护理和罕见疾病。</p>
</div><h2>Featured Stories</h2>
<div class="lb-trans"><h2>精选故事</h2>
</div><ul>
<li>Five stocks we like better than Novo Nordisk A/S</li>
<li>How Can Retail Investors Trade the Toronto Stock Exchange (TSX)?</li>
<li>Tariff Exemptions Set the Stage for a Taiwan Semiconductor Rally</li>
<li>Most Volatile Stocks, What Investors Need to Know</li>
<li>Mitigating Tariffs: 3 Stocks to Gain From a Weaker U.S. Dollar</li>
<li>How to Invest in Small Cap Stocks</li>
<li>Broadcom’s Apple Relationship: AI Opportunity Meets Tariff Risk</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票超过诺和诺德公司</li>
<li>零售投资者如何交易多伦多证券交易所（TSX）？</li>
<li>关税豁免为台湾半导体的反弹铺平了道路</li>
<li>最具波动性的股票，投资者需要知道的事项</li>
<li>缓解关税：三只股票将从美元走弱中受益</li>
<li>如何投资小型股</li>
<li>博通与苹果的关系：人工智能机会与关税风险</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPU5WTw" alt="" original-src="https://www.marketbeat.com/scripts/RatingsChart.ashx?Prefix=NYSE&amp;Symbol=NVO"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前经过 MarketBeat 编辑团队的审核。如对该故事有任何问题或意见，请发送电子邮件至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Novo Nordisk A/S Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在诺和诺德公司吗？</h2>
</div><p>Before you consider Novo Nordisk A/S, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑诺和诺德公司之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Novo Nordisk A/S wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，以便在更广泛的市场注意到之前进行购买……而诺和诺德公司并不在名单上。</p>
</div><p>While Novo Nordisk A/S currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然诺和诺德公司目前在分析师中被评为持有评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看这五只股票</p>
</div>

诺和诺德公司（NYSE:NVO）获得分析师一致建议为 “持有”